Metabolism of amprenavir in liver microsomes: Role of CYP3A4 inhibition for drug interactions

Journal of Pharmaceutical Sciences

Volumn 87, Issue 7, 1998, Pages 803-807

  Decker, Caroline J ^a   Laitinen, Leena M ^a   Bridson, Gary W ^a   Raybuck, Scott A ^a   Tung, Roger D ^a   Chaturvedi, Pravin R ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ASTEMIZOLE; COTRIMOXAZOLE; CYTOCHROME P450; INDINAVIR; KETOCONAZOLE; METHADONE; NELFINAVIR; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; TERFENADINE;

ARTICLE; CONTROLLED STUDY; DRUG MIXTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER MICROSOME; VIRUS REPLICATION;

EID: 0031820026     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js980029p     Document Type: Article

References (28)

1. Cameron, G.; Heath-Chiozzi, M.; Kravcik, S.; Mills, R.; Potthoff, A.; Henry, D. The advanced HIV ritonavir study group. Presented at the 3rd Conference on Retroviruses and Opportunistic Infections, Washington, D.C., Jan 28-Feb 1, 1996.
2. Leonard, J. Prolongation of life and prevention of AIDS in advanced immunodeficiency with ritonavir. Presented at the 3rd Conference on Retroviruses and Opportunistic Infections, Washington, B.C., Jan 28-Feb 1, 1996.
3. Gulick, R. M.; Mellors, J. W.; Havlir, D.; Eron, J. J.; Gonzalez, C.; McMahol, D.; Richman, D. D.; Valentine, F. T.; Jonas, L.; Meibohm, A.; Emini, E. A.; Chodakewitx, J. Z. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New Eng. J. Med. 1997, 337, 734-739.
4. Fauci, A. S.; Goosby, E. P.; Smith, M. D. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Fed. Regist. 1996, 61,.
5. Battegay, M.; Bernascon, E.; Flepp, M.; Vernazza, P.; Malinverni, R.; Zanetti, G.; Morgenthaler, S.; Perret, V.; Hirschel, B. Swiss HIV cohort study. A pilot study of saquinavir in combination with ritonavir and d4T in patients with advanced HIV disease. Proceedings of the Interscience Confer-ence on Antimicrobial Agents and Chemotherapy, September, 1997, Toronto Canada; I203.
6. Batisse, D.; Salmon-Seron, S.; Karmochkine, M.; Ginsburg, C.; Castiel, P.; Raguin, G.; Weiss, L.; Sicard, D.; Kazatchkine, M. D. Efficacy and safety of ritonavir and saquinavir in combination in protease inhibitor-experienced patients. Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy, September, 1997, Toronto, Canada; I206.
7. Deeks, S.; Grant, R.; Horton, C.; Simmonds, N.; Follansbee, S.; Eastman, S. Virologic effect of ritonavir plus saquinavir in subjects who have failed indinavir. Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy, September, 1997, Toronto, Canada; I205.
8. Livingston, D. J.; Pazhanisamy, S.; Porter, D. J. T, Partaledis, J. A.; Tung, R. D.; Painter, G. R. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J. Infect. Dis. 1996, 172, 1238-1245.
9. Studenberg, S. D.; Dahl, R. R.; Wooley, J. L. Pharmacokinetics, excretion, and mass balance studies in dogs with 14C-141W94 (VX-478), an HIV-1 protease inhibitor. International Society for the study of Xenobiotics (ISSX) Proceedings, October, 1996, San Diego, CA.
10. Barry, M. Gibbons, S.; Back, D.; Mulcahy, F. Protease inhibitors in patients with HFV disease. Clinically important pharmacokinetic considerations. Clin. Pharmacokinet. 1997, 32(3), 194-290.
11. Kumar, G. N.; Rodreigues, A. D.; Buko, A. M.; Denissen, J. F. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Therapeut. 1996, 277, 423-431.
12. Farrar, G.; Mitchell, A. M.; Hooper, H.; Stewart, F.; Malcolm, S. L. Prediction of potential drug interactions of saquinavir from in vitro data. Proceedings of the BPS12-13, 1994; 162P.
13. Fitzsimmons, M. E.; Collins, J. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome CYP3A4. Potential contribution to high first-pass metabolism. Drug Metab. Dispos. 1997, 25(2), 256-266.
14. Eagling, V. A.; Back, D. J.; Barry, M. G. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br. J. Clin. Pharmacol. 1997, 44, 190-194.
15. Chiba, M.; Hensleigh, M.; Nishime, J. A.; Balani, S. K.; Lin, J. H. Role of Cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. 1996, 24(3), 307-314.
16. Wu, E-Y, Sandoval, T. M.; Lee, C. A.; Zhang, K.; Liang, B. H. Grettenberger, H. M.; Hee, B.; Shetty, B. V. In vitro metabolism studies with the HIV-1 protease inhibitor, Viracept (nelfinavir). International Society for the study of Xenobiotics (ISSX) Proceedings, October, 1996, San Diego, CA.
17. Kempf, D. J.; Marsh, K. C.; Kumar, G.; Rodrigues, A. D.; Denissen, J. F.; McDonald, E.; Kukulka, M. J.; Hsu, A.; Granneman, G. R.; Baroldi, P. A.; Sun, E.; Pizzuti, D.; Plattner, J. J.; Norbeck, D. W.; Leonard, J. M. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by co-administration with ritonavir. Antimicrob. Agents Chemother. 1997, 41(3), 654-600.
18. Newton, D. J.; Wang, R. W.; Lu, A. Y. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 1995, 23(1), 154-158.
19. Woolley, J.; Studenberg, S.; Boehlert, C.; Bowers, G.; Sinahababu, A.; Adams, P. Cytochrome P-450 isozyme induction, inhibtion, and metabolism studies with the HIV protease inhibitor, 141W94. Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy, September, 1997, Toronto, Canada; A-60.
20. Polk, R. E.; Israel, D. S.; Pastor, A.; Sadler, B. M.; Chittick, G. E.; Symonds, W. T.; Crouch, M.; Gouldin, W.; Lou, Y.; Rawls, C.; Bye, A. Pharmacokinetic interation between ketoconazole and HIV protease inhibitor 141W94 after single dose administration to normal volunteers. Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy, September, 1997, Toronto, Canada; A-61.
21. Heylen, R.; Miller, R. Adverse effects and drug interactio 1ns of medications commonly used in the treatment of adult HIV positive patients: Part 2. Genitourin. Med. 1997, 73, 5-11.
22. Norvir (ritonavir) product information, 1996, Abbott Laboratories: Waukegan, IL.
23. Crixivan (indinavir) product information, 1996, Merck Sharp & Dohme: Rahway, NJ.
24. Viracept (nelfinavir) product information, 1997, Agouron Pharmaceuticals: San Diego, CA.
25. Sadler, B. H.; Elkins, M.; Hanson, C.; Rooney, J.; Millard, J.; Blum, M. R.; Painter, G. R. The safety and pharmacokinetics of 141W94: An HIV protease inhibitor. Presented at the 5th European Conference on Clinical Aspects of Treatment of HIV Infection, Sept 26-29, 1995, Copenhagen; Abstract 564.
26. Polk, R. E. Israel, D. S.; Patron, R.; Sadler, B. M.; Chittick, G. E.; Symonds, W. T.; Brophy, D.; Kristoff, D.; Lou, Y.; Bye, A. Pharmacokinetic (PK) interaction between 141W94 and rifabutin (RFB) and rifampin (RFP) after multiple-dose administration. Presented at the 5th Conference on Retroviruses and Opportunistic Infections, Feb 1-5, 1998, Chicago; Abstract 340.
27. Polk, R. E.; Israel, D. S.; Pastor, A.; Sadler, B. M.; Chittick, G. E.; Symonds, W. T.; Crouch, M.; Gouldin, W.; Lou, Y.; Rawls, C., Bye, A. Pharmacokinetic (PK) interaction between ketoconazole (KCZ) and the HIV protease inhibitor 141W94 after single dose administration to normal volunteers. Proceedings of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Sept 28-Oct 1, 1997, Toronto; Abstract A-61.
28. Sadler, B. M.; Eron, J.; Wakeford, J.; Pagano, G.; Rawls, C.; McCrea, J.; Mazina, K.; Deutsch, P. J. Pharmacokinetics of 141W94 and indinavir (IDV) after single-dose coadministration in HIV-positive volunteers. Proceedings of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Sept 28-October 1, 1997, Toronto; Abstract A-56.